JMJD8 and hepatocellular carcinoma: Another study proved that the expressions of USP22 and Jumonji domain-containing protein 8 (JMJD8) were elevated in HCC cells resistant to lenvatinib, and USP22 and JMJD8 formed a regulatory axis that regulated LR by altering apoptosis-related protein c-Myc 32.